Jacques Rachelle Suzanne — SEC Form 4 filings
SEC reporting owner CIK 1772610. 10 Form 4 filings on record with FilingPulse; latest filed 2026-06-12.
Transaction summary — filings shown
Covers all 10 filings on record, filed 2024-04-30 to 2026-06-12. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 3 legs across 3 filings — 6,326 shares, $95,865 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 13.
- Largest priced transaction: sale of 1,993 shares @ $27.06 ($53,931) in uniQure N.V., filed 2026-06-12.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| uniQure N.V. (QURE) | Director | 5 | — | 3 legs · 6,326 sh · $95,865 | 6 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | Director | 4 | — | — | 6 |
| Akari Therapeutics Plc (AKTX) | Chief Executive Officer, Director | 1 | — | — | 1 |
Form 4 filings — Jacques Rachelle Suzanne
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-06-12 | 4 | uniQure N.V. (QURE) | Grant/award (A): 7,550 @ $0 · Sale (S): 1,993 @ $27.06 · Grant/award (A): 13,980 (derivative) @ $0 | EDGAR |
| 2026-05-21 | 4 | Corbus Pharmaceuticals Holdings, Inc. (CRBP) | Grant/award (A): 3,800 @ $0 · Grant/award (A): 12,300 (derivative) @ $0 | EDGAR |
| 2025-06-24 | 4 | uniQure N.V. (QURE) | Sale (S): 2,112 @ $14.45 | EDGAR |
| 2025-06-13 | 4 | uniQure N.V. (QURE) | Grant/award (A): 7,970 @ $0 · Grant/award (A): 15,630 (derivative) @ $0 | EDGAR |
| 2025-06-02 | 4 | Corbus Pharmaceuticals Holdings, Inc. (CRBP) | Grant/award (A): 4,800 @ $0 · Grant/award (A): 16,000 (derivative) @ $0 | EDGAR |
| 2024-06-21 | 4 | uniQure N.V. (QURE) | Grant/award (A): 8,080 @ $0 · Grant/award (A): 15,840 (derivative) @ $0 | EDGAR |
| 2024-06-17 | 4 | uniQure N.V. (QURE) | Sale (S): 2,221 @ $5.14 | EDGAR |
| 2024-06-03 | 4 | Corbus Pharmaceuticals Holdings, Inc. (CRBP) | Grant/award (A): 2,783 @ $0 | EDGAR |
| 2024-05-20 | 4 | Corbus Pharmaceuticals Holdings, Inc. (CRBP) | Grant/award (A): 2,783 (derivative) @ $0 | EDGAR |
| 2024-04-30 | 4 | Akari Therapeutics Plc (AKTX) | Grant/award (A): 479,569,892 @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1772610 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →